Key result
Hemato-lymphoid malignancies were associated with a higher incidence of pediatric cancer-associated thrombosis compared to solid tumors (3.23% vs. 1.58%; OR 2.06; 95% CI 1.36-2.88; p<.001).
Why the study?
Thrombotic events have been extensively studied in adult cancer patients, but data in children are limited.
What is the incidence and what are the risk factors for pediatric cancer-associated thrombosis in children with malignancies?
Cohort (n=6,132)
No
What is the incidence and what are the risk factors for pediatric cancer-associated thrombosis in children with malignancies?
Odds Ratio: 2.06 (95% CI 1.36–2.88)
Absolute Event Rate: 3.23% vs 1.58%
p-value: p=<.001
Pediatric cancer-associated thrombosis occurs in 2.4% of children with malignancies, predominantly in older children with hematolymphoid malignancies, and is associated with reduced event-free survival.
May inform thrombosis risk stratification in pediatric oncology; leaves open prospective evaluation of preventive strategies.
No takes yet. Share an insight, caveat, or question.
Dhariwal et al. (2022) conducted a cohort in Pediatric cancer-associated thrombosis (n=6,132). Hemato-lymphoid malignancies vs. Solid tumors was evaluated on Pediatric cancer-associated thrombosis (PCAT) (OR 2.06, 95% CI 1.36-2.88, p=<.001). Hemato-lymphoid malignancies were associated with a higher incidence of pediatric cancer-associated thrombosis compared to solid tumors (3.23% vs. 1.58%; OR 2.06; 95% CI 1.36-2.88; p<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: